An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast and gastric cancers and this causes poor clinical outcomes. Although both T‐DM1 and Enhertu are approved as an HER2‐targeting antibody‐drug conjugate (ADC), the effects of these drugs are still not satisfactory to eradicate d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Seol Hwa, Park, Yun‐Hee, Park, Seok Soon, Ju, Eun Jin, Park, Jin, Ko, Eun Jung, Bae, Dong Jun, Kim, Sang‐Yeob, Chung, Chul‐Woong, Song, Ho Young, Jang, Se Jin, Jeong, Seong‐Yun, Song, Si Yeol, Choi, Eun Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655175/
https://www.ncbi.nlm.nih.gov/pubmed/34664433
http://dx.doi.org/10.1002/advs.202102414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655175/
https://www.ncbi.nlm.nih.gov/pubmed/34664433
http://dx.doi.org/10.1002/advs.202102414

Ejemplares similares